Keeping one step ahead of the innovators

There can't be many people in the hedge fund industry that could comfortably say they know what makes a good investment in the realm of biotechnology.

The producers in the industry are necessarily cagey about what they are working on, and most, if not all, hedge fund managers probably wouldn't fully understand it. Most investors, that is.

Michael Walsh, founder of Kilkenny Capital Management, is different. Not just another hedge fund manager, he is a chemist with a Harvard MBA who can shed light

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

If you already have an account, please sign in here.


Want to know what’s included in our free registration? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here